These Drug Prices Won't Soon Go Down—Here's Why
That's because Congress changed the law to outright exempt or delay consideration of more than 300 medications for the Medicare Drug Price Negotiation Program.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
UnitedHealth Stock (UNH) Rises as Investors Welcome Dividend Approval
UnitedHealth (UNH), a health care and insurance provider, has received board approval to pay its next quarterly cash dividend of $2.10 per share. The move reflects UNH's efforts to boost shareholders' returns despite dealing with rising medical costs and intense regulatory scrutiny. UNH stock was up 3.1% on Wednesday morning. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company announced that it will pay the dividend on March 18, 2025, to all shareholders of record as of March 10, 2025. It must be noted that UnitedHealth has a consistent dividend track record, which now spans over 15 years. Based on yesterday's closing price of $261.57, UnitedHealth's current dividend yield is nearly 3.21%. Importantly, it remains above the Healthcare sector's average of 1.82%. Dividend Approved Despite Headwinds The dividend approval comes as UnitedHealth continues to face rising medical costs, increased regulatory scrutiny, and broader uncertainty across the healthcare sector. The company's troubles began when it slashed its full-year 2025 earnings forecast after reporting a steep drop in Q2 profits, driven largely by higher-than-expected medical costs. These expenses surged across both Medicare Advantage and commercial plans, prompting UnitedHealth to reevaluate its pricing and benefit structures. The company now expects $6.5 billion in additional medical costs this year, with ripple effects likely to stretch into 2026. As a result, UnitedHealth is exiting certain Medicare Advantage markets, impacting roughly 600,000 enrollees. Meanwhile, the Department of Justice is investigating UNH's Medicare billing practices. Despite these headwinds, the company states that its long-term growth plan remains on track, with a focus on AI tools and enhancing patient care. Is UNH a Good Buy Right Now? average UnitedHealth stock price target implies a 25.36% upside potential.
Business Upturn
7 hours ago
- Business Upturn
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the 'Class Period'), of the important September 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Centene securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Centene class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene's expected revenue guidance and adjusted diluted earnings per share ('EPS') for the 2025 fiscal year. Defendants' statements included, among other things, confidence in Centene's enrollment and morbidity rates, as well as strong retention rates in Centene's Medicare business. Defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Centene class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Wall Street Journal
9 hours ago
- Wall Street Journal
How to End the Tariff Debate
While I find the editorial board's legal reasoning more persuasive than Chad Squitieri's ('President Trump's Tariffs Are on Solid Ground,' Letters, Aug. 9), the law professor is right that Congress should resolve this question now. Given the economic harm and uncertainty caused by IEEPA levies, Congress should awaken from its dormancy and amend the law to specify that it can't be used to justify tariffs. Proactively amending IEEPA has the added benefit of ensuring that a court doesn't unduly limit the president's authority under this important statute beyond what Congress intends. Ben Richmond
